Suscribirse

Status Epilepticus in Central Nervous System Infections: An Experience From a Developing Country - 20/08/11

Doi : 10.1016/j.amjmed.2008.02.012 
Usha Kant Misra, MD, DM , Jayantee Kalita, MD, DM, Pradeep P. Nair, MD, DM
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. 

Requests for reprints should be addressed to Usha Kant Misra, MD, DM, Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareily Road, Lucknow 226014, India.

Abstract

Objective

There is a paucity of comprehensive study in status epilepticus in central nervous system infections. This observational study evaluated the response to antiepileptic drugs in patients with status epilepticus and central nervous system infection.

Methods

The study took place at a tertiary care teaching hospital in India. A total of 37 of 93 adult patients (39.8%) with status epilepticus had central nervous system infection, and they underwent clinical evaluation, including status type and duration. Magnetic resonance imaging and cerebrospinal fluid analyses were performed. Patients were categorized into encephalitis, meningitis, and granuloma groups. The response to antiepileptic drugs was noted, and the status was considered refractory if seizures continued after the second antiepileptic drug. Refractory status epilepticus and mortality were correlated with the type of infection and various clinical and magnetic resonance imaging findings.

Results

The median age of the patients was 37 years (16-78 years), and 17 patients were female; 35 patients had convulsive status epilepticus, and 2 patients had nonconvulsive status epilepticus. Twenty patients had encephalitis (Japanese 4, herpes simplex 3, nonspecific 12), including 1 patient with malaria, 9 patients with meningitis (tubercular 5, pyogenic 3, fungal 1), and 7 patients with granuloma (tubercular 5, neurocysticercosis 2). The mean duration of status epilepticus was 19.6 hours (0.25-72 hours). Magnetic resonance imaging results were abnormal in 66.7% of patients. In 67.6% of patients, status epilepticus was controlled after the first antiepileptic drug. Some 24.3% of patients were refractory to the second antiepileptic drug, and 10.8% of patients did not respond to the third antiepileptic drug. Patients with encephalitis had an insignificantly poor response. Eleven patients (29.7%) died, and mortality was higher in patients with refractory status epilepticus.

Conclusion

Of patients with status epilepticus and central nervous system infection, 24.3% had a refractory status that was associated with a high mortality. Their response to an antiepileptic drug in encephalitis was insignificantly poorer.

El texto completo de este artículo está disponible en PDF.

Keywords : Antiepileptic drug, Electroencephalography, Encephalitis, Granuloma, Meningitis, Mortality, Outcome, Refractory status, Status epilepticus


Esquema


© 2008  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 121 - N° 7

P. 618-623 - juillet 2008 Regresar al número
Artículo precedente Artículo precedente
  • Pulmonary Embolism Incidence Is Increasing with Use of Spiral Computed Tomography
  • Nicholas A. DeMonaco, Qianyu Dang, Wishwa N. Kapoor, Margaret V. Ragni
| Artículo siguiente Artículo siguiente
  • Cryofibrinogen in Patients with Hepatitis C Virus Infection
  • Aurélien Delluc, David Saadoun, Pascale Ghillani-Dalbin, Damien Sene, Jean Charles Piette, Patrice Cacoub

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.